Tesofensine Evidence Guide
Tesofensine completed a Phase 2b trial showing 10.6% weight loss at 0.5mg over 24 weeks - a clinically meaningful result that outperforms most non-GLP-1 agents. The triple monoamine reuptake inhibition mechanism is distinct from incretin-based approaches, making it relevant for patients who respond poorly to GLP-1 agonists. Phase 3 completion is the outstanding question, but the Phase 2b signal is genuine.
Our Take
Tesofensine completed a Phase 2b trial showing 10.6% weight loss at 0.5mg over 24 weeks - a clinically meaningful result that outperforms most non-GLP-1 agents. The triple monoamine reuptake inhibition mechanism is distinct from incretin-based approaches, making it relevant for patients who respond poorly to GLP-1 agonists. Phase 3 completion is the outstanding question, but the Phase 2b signal is genuine.
- Best for
- Non-GLP-1 weight loss research, monoamine reuptake inhibition pharmacology, obesity treatment alternatives
- Evidence grade
- Level B
- Confidence
- Moderate
- Starting point
- 0.25mg oral daily, titrated to 0.5mg
Benefits and Evidence
- Body Weight Reduction: Level B, includes human evidence - Phase 2 trials demonstrated dose-dependent weight loss: 4.5% (0.25 mg), 9.2% (0.5 mg), and 10.6% (1.0 mg) at 24 weeks, approximately twice the effect of existing approved anti-obesity medications at the time.
- Appetite Suppression: Level B, includes human evidence - Significant reduction in self-reported hunger and food intake through triple monoamine reuptake inhibition affecting hypothalamic appetite centers.
- Cardiovascular Effects: Level B, includes human evidence - Dose-dependent increases in heart rate (5-8 bpm) and blood pressure observed, attributed to noradrenergic enhancement. This is a key safety concern limiting development.
Side Effects and Warnings
- Dry mouth
- Insomnia
- Constipation
- Increased heart rate
- Elevated blood pressure
- Nausea
- Diarrhea
- Headache
Research Dosage References
- <strong>Oral</strong> - 0.25-0.5 mg - Once daily - The 0.5 mg dose showed the best benefit-risk ratio in Phase 2 trials. The 1.0 mg dose produced more weight loss but with increased cardiovascular side effects.
Mechanism of Action
Tesofensine inhibits the presynaptic reuptake of three monoamine neurotransmitters: serotonin (5-HT), norepinephrine (NE), and dopamine (DA). By blocking the respective transporters (SERT, NET, and DAT), it increases synaptic concentrations of all three neurotransmitters simultaneously. The serotonergic enhancement promotes satiety through 5-HT2C receptor activation in the hypothalamic arcuate nucleus, reducing appetite and food intake. Noradrenergic enhancement increases sympathetic tone, elevating resting metabolic rate and promoting thermogenesis through beta-adrenergic receptor activation in brown adipose tissue. The dopaminergic component is believed to reduce hedonic eating and food reward-seeking behavior by modulating the mesolimbic reward pathway. This triple mechanism addresses multiple neurobiological drivers of overeating simultaneously, which may explain the superior weight loss efficacy compared to agents targeting only one or two neurotransmitter systems. Tesofensine also has a long-acting active metabolite (M1) that contributes to sustained pharmacological activity throughout the dosing interval.
Legal Status
Not approved in any jurisdiction. Phase 3 clinical trials ongoing. Not a controlled substance.
Primary Sources
- Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. The Lancet, 2008.
- Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression and weight loss in obese patients. International Journal of Obesity, 2010.